Equities researchers at Barclays Capital increased their price target on shares of Illumina (NASDAQ:ILMN) from $55.00 to $80.00 in a research report issued on Monday, ARN reports. The firm currently has an “overweight” rating on the stock. Barclays Capital’s price target would suggest a potential upside of 7.05% from the company’s current price.
ILMN has been the subject of a number of other recent research reports. Analysts at Piper Jaffray Cos. downgraded shares of Illumina from an “overweight” rating to a “neutral” rating in a research note to investors on Tuesday, July 2nd. They now have a $70.00 price target on the stock, up previously from $61.00. They noted that the move was a valuation call. Separately, analysts at Goldman Sachs Group Inc. reiterated a “neutral” rating on shares of Illumina in a research note to investors on Thursday, June 27th. They now have a $64.00 price target on the stock, up previously from $59.00. Finally, analysts at Credit Suisse downgraded shares of Illumina from a “focus list” rating to an “outperform” rating in a research note to investors on Tuesday, June 11th.
One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $64.32.
Shares of Illumina (NASDAQ: ILMN) opened at 74.73 on Monday. Illumina has a 52 week low of $40.43 and a 52 week high of $78.24. The stock’s 50-day moving average is currently $72.36. The company has a market cap of $9.295 billion and a P/E ratio of 96.05.
Illumina, Inc (NASDAQ: ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.